Oncoloxía médica

2014

1. 10th congress on lung cancer-Updates on clinical trials: Goal

   Translational Lung Cancer Research, Vol. 3, Núm. 2, pp. 66-69

2. A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond

   Cancer Letters, Vol. 351, Núm. 1, pp. 30-40

3. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer

   International Journal of Cancer, Vol. 135, Núm. 11, pp. 2633-2643

4. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): A Galician Lung Cancer Group (GGCP) study

   Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 3, pp. 451-457

5. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

   PLoS ONE, Vol. 9, Núm. 9

6. Aplicación de la topología molecular a la predicción y optimización de la actividad repelente de mosquitos de derivados de la N-acypiperidina

   Nereis: revista iberoamericana interdisciplinar de métodos, modelización y simulación, Núm. 6, pp. 19-26

7. Biosensors for the detection of circulating tumour cells

   Sensors (Switzerland), Vol. 14, Núm. 3, pp. 4856-4875

8. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: Final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

   BMC Cancer, Vol. 14, Núm. 1

9. Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study)

   Bone, Vol. 68, pp. 32-40

10. Breast cancer management in the elderly

    Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 351-361

11. CA15.3 serum concentrations in older women with infiltrating ductal carcinomas of the breast

    International Journal of Molecular Sciences, Vol. 15, Núm. 11, pp. 19870-19876

12. Cabazitaxel for metastatic castration-resistant prostate cancer: Safety data from the Spanish expanded access program

    Expert Opinion on Drug Safety, Vol. 13, Núm. 9, pp. 1165-1173

13. Cambios histológicos implicados en metástasis

    International Journal of Morphology, Vol. 32, Núm. 3, pp. 935-941

14. Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer

    Future Oncology, Vol. 10, Núm. 7, pp. 1187-1202

15. Clinical guideline SEOM: cancer of unknown primary site

    Clinical and Translational Oncology, Vol. 16, Núm. 12, pp. 1091-1097

16. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: Results from the GEICAM 9906 trial

    Breast Cancer Research, Vol. 16, Núm. 2

17. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy

    Tumori, Vol. 100, Núm. 2, pp. 225-231

18. ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas

    Carcinogenesis, Vol. 35, Núm. 12, pp. 2679-2686

19. El consentimiento por ‘medios simplificados’ en la nueva reglamentación europea de ensayos clínicos

    Actualidad del derecho sanitario, Núm. 217, pp. 581-585

20. Emesis y quimioterapia. Más allá de los setrones y los antagonistas del receptor NK1

    Revisiones en Cancer, Vol. 28, Núm. 4, pp. 175-183